<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84906782781</prism:url><dc:identifier>SCOPUS_ID:84906782781</dc:identifier><eid>2-s2.0-84906782781</eid><pubmed-id>24998941</pubmed-id><prism:doi>10.1016/j.jconrel.2014.06.043</prism:doi><dc:title>Ocular delivery of macromolecules</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>3</citedby-count><prism:publicationName>Journal of Controlled Release</prism:publicationName><dc:publisher>
Elsevier
</dc:publisher><source-id>23010</source-id><prism:issn>18734995</prism:issn><prism:volume>190</prism:volume><prism:startingPage>172</prism:startingPage><prism:endingPage>181</prism:endingPage><prism:pageRange>172-181</prism:pageRange><prism:coverDate>2014-09-28</prism:coverDate><dc:creator><author auid="56072516700" seq="1"><ce:initials>Y.C.</ce:initials><ce:indexed-name>Kim Y.C.</ce:indexed-name><ce:surname>Kim</ce:surname><ce:given-name>Yoo Chun</ce:given-name><preferred-name>
<ce:initials>Y.C.</ce:initials>
<ce:indexed-name>Kim Y.</ce:indexed-name>
<ce:surname>Kim</ce:surname>
<ce:given-name>Yoo Chun</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56072516700</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng">
<ce:para>Biopharmaceuticals are making increasing impact on medicine, including treatment of indications in the eye. Macromolecular drugs are typically given by physician-administered invasive delivery methods, because non-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailability and/or poor ocular targeting. There is a need to improve delivery of biopharmaceuticals to enable less-invasive delivery routes, less-frequent dosing through controlled-release drug delivery and improved drug targeting within the eye to increase efficacy and reduce side effects. This review discusses the barriers to drug delivery via various ophthalmic routes of administration in the context of macromolecule delivery and discusses efforts to develop controlled-release systems for delivery of biopharmaceuticals to the eye. The growing number of macromolecular therapies in the eye needs improved drug delivery methods that increase drug efficacy, safety and patient compliance. Â© 2014 Elsevier B.V.</ce:para>
</abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84906782781" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84906782781&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84906782781%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"><affilname>Georgia Institute of Technology</affilname></affiliation><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60073619" id="60073619"><affilname>Shandong Eye Institute and Hospital</affilname></affiliation><authors><author auid="56072516700" seq="1"><ce:initials>Y.C.</ce:initials><ce:indexed-name>Kim Y.C.</ce:indexed-name><ce:surname>Kim</ce:surname><ce:given-name>Yoo Chun</ce:given-name><preferred-name>
<ce:initials>Y.C.</ce:initials>
<ce:indexed-name>Kim Y.</ce:indexed-name>
<ce:surname>Kim</ce:surname>
<ce:given-name>Yoo Chun</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56072516700</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"/></author><author auid="56178240300" seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Chiang B.</ce:indexed-name><ce:surname>Chiang</ce:surname><ce:given-name>Bryce</ce:given-name><preferred-name>
<ce:initials>B.</ce:initials>
<ce:indexed-name>Chiang B.</ce:indexed-name>
<ce:surname>Chiang</ce:surname>
<ce:given-name>Bryce</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56178240300</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"/></author><author auid="56268695400" seq="3"><ce:initials>X.</ce:initials><ce:indexed-name>Wu X.</ce:indexed-name><ce:surname>Wu</ce:surname><ce:given-name>Xianggen</ce:given-name><preferred-name>
<ce:initials>X.</ce:initials>
<ce:indexed-name>Wu X.</ce:indexed-name>
<ce:surname>Wu</ce:surname>
<ce:given-name>Xianggen</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56268695400</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60073619" id="60073619"/></author><author auid="7006199362" seq="4"><ce:initials>M.R.</ce:initials><ce:indexed-name>Prausnitz M.R.</ce:indexed-name><ce:surname>Prausnitz</ce:surname><ce:given-name>Mark R.</ce:given-name><preferred-name>
<ce:initials>M.R.</ce:initials>
<ce:indexed-name>Prausnitz M.</ce:indexed-name>
<ce:surname>Prausnitz</ce:surname>
<ce:given-name>Mark R.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7006199362</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60019647" id="60019647"/></author></authors></abstracts-retrieval-response>
